Key facts
- This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for Atreca, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 23 Oct 2023, 16:49.
BAKER BROS. ADVISORS LP - 19 Oct 2023 Form 4 Insider Report for Atreca, Inc.
- Reporting relationship
- Former 10% Owner
- Issuer ticker
- N/A
- Reported as of
- 19 Oct 2023
- Net transaction value
- -$110,582
- SEC form
- 4
- Accepted by SEC
- 23 Oct 2023, 16:49:08 UTC
- Prior SEC filing
- 10 Oct 2023
- Next SEC filing
- 15 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
BAKER BROS. ADVISORS LP filed Form 4 for Atreca, Inc. on 23 Oct 2023.
Change
- Previous filing in this sequence was filed on 10 Oct 2023.
- Current net transaction value: -$110,582.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCEL
transaction
Class A common stock
Sale
- Transaction value
- $9,192
- Shares
- -22,837
- Change %
- -7.4%
- Price
- $0.4025
- Shares after
- 286,893
- Date
- 19 Oct 2023
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4
BCEL
transaction
Class A common stock
Sale
- Transaction value
- $101,391
- Shares
- -251,902
- Change %
- -7.8%
- Price
- $0.4025
- Shares after
- 2,971,128
- Date
- 19 Oct 2023
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
BAKER BROS. ADVISORS LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares of Class A common stock ("Class A common stock") of Atreca, Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $0.37 to $0.42, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Footnote F2
After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A common stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Footnote F3
Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
Footnote F4
Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Footnote F5
After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A common stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.